The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis

Yara Dadalti Fragoso1, Christian Cardoso Arruda2, Walter Oleschko Arruda3, Joseph Bruno Bidin Brooks1, Alfredo Damasceno4, Carlos Augusto de Albuquerque Damasceno5, Alessandro Finkelsztejn6, Juliana Finkelsztejn6, Paulo Diniz da Gama7, Maria Cristina Brandão Giacomo8, Sidney Gomes9, Marcus Vinicius Magno Gonçalves10, Andre Palma da Cunha Matta11, Marilícia Manprim de Morais12, Enedina Maria Lobato de Oliveira12, Yuna Ribeiro13, Henry Koiti Sato14, Carlos Bernardo Tauil13

ABSTRACT

Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.

Keywords: multiple sclerosis, fingolimod, bradycardia, adverse event.

The efficacy of fingolimod, the innovative oral drug therapy for multiple sclerosis (MS) has been shown in clinical trials and in medical practice. It is widely recommended that, during the first dose of fingolimod, patients should be on an appropriate
medical environment capable to deal with potential cardiovascular complications. Transient effects on heart rate are explained by transient agonism of sphingosine-1P receptors in atrial myocytes. As yet, there has been no report on the safety of the first dose of fingolimod in Brazilian patients with MS where the protocol recommends medical observation and cardiovascular monitoring for at least six hours. In fact, except for results on clinical trials with very strict inclusion criteria for patients, there are few reports on the real life experience with the first dose of fingolimod.

Retrospective data were collected for 180 patients aged over 18 years diagnosed with MS according to the revised McDonald criteria. These patients were closely monitored during the first dose of fingolimod. Each MS Unit had obtained authorization by the Ethics Committee to proceed with the treatment with fingolimod. Patients were informed that they should contact their doctor in case of any signs or symptoms beyond the observation period (minimum six hours).

Gender, age, cardiac rate and blood pressure were registered for all cases. There were 132 women and 48 men, with an average age of 36.8 years (median=36 years, range=19 to 66 years). Five patients had high blood pressure and four patients had right or left branch block before medication. They were kept under observation for longer than six hours and did not develop complications. Two patients had sinus tachycardia and two other patients had sinus bradycardia at the first ECG registration. They did not develop complications. Twelve other patients (6.7%) were kept under medical observation for longer than six hours due to symptomatic bradycardia, while three of them (1.7%) needed to be in intensive care units for developing right branch block or second-degree atrioventricular block. There were no cases of other severe complications and no cases of death among these patients during or after the initial dose, despite the description of possible delayed asystole. At present, 99.4% of the patients reported here continue the treatment with fingolimod.

Figure shows a summary of data regarding cardiac rate, systolic and diastolic blood pressure up to six hours for all patients. When assessed by one-way ANOVA, the 3rd and 4th hours of observation showed a significant ($P<0.001$) lower heart rate than other time points.

Figure also shows the variation in systolic and diastolic blood pressure during the observation period of six hours. There were no isolated cases of marked hypo or hypertension peaks during the whole observation period. When assessed by one-way ANOVA, no significant differences in either systolic or diastolic blood pressure were observed.

The FREEDOMS clinical trial of fingolimod and its extensions showed less than 1% cases of bradycardia during the first dose. The study of Ontaneda et al. which dealt with clinical practice data also demonstrated 1% rate of bradycardia as a complication of fingolimod initiation. A recent Italian study reported 2% cardiovascular adverse events in patients taking the first dose of fingolimod, mainly bradycardia and atrio-ventricular block. The Italian study used a method similar to ours, reporting the results of daily medical practices. For Brazilian patients in the real life series this observation was higher, even though there was a return to normal cardiac rate after a period of up to ten hours in all but three cases.

![Figure](image_url)
It is imperative to register the cardiovascular parameters during the first dose of fingolimod. A much larger retrospective and prospective Brazilian database should be created in order to observe cardiovascular parameters in patients receiving the first dose of fingolimod in our country.

Acknowledgments

The authors are grateful to all cardiologists who graciously sent data from patients seen at first dose clinical units in Brazil.

References